[{"id":"f4b4cbe0-4811-4846-aa3a-c12b65f5b2a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052618","created_at":"2023-09-25T14:10:30.120Z","updated_at":"2025-02-25T12:29:50.276Z","phase":"Phase 2","brief_title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","source_id_and_acronym":"NCT06052618","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 01/01/2033","primary_completion_date":" 01/01/2033","study_txt":" Completion: 01/01/2034","study_completion_date":" 01/01/2034","last_update_posted":"2025-02-24"},{"id":"6b19c0a6-ae66-4201-9c5b-978c28f8c121","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514484","created_at":"2021-01-18T21:38:07.896Z","updated_at":"2025-02-25T16:45:04.992Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","source_id_and_acronym":"NCT04514484","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD276 • VTCN1 • CD4 • HHLA2","pipe":"","alterations":" ","tags":["CD276 • VTCN1 • CD4 • HHLA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/02/2025","primary_completion_date":" 11/02/2025","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2025-02-05"},{"id":"a89a199c-8105-44bd-a321-b07e9e8b9417","acronym":"NCI-2018-02529","url":"https://clinicaltrials.gov/study/NCT03316274","created_at":"2021-01-18T16:22:38.781Z","updated_at":"2025-02-25T14:37:35.336Z","phase":"Phase 1","brief_title":"Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma","source_id_and_acronym":"NCT03316274 - NCI-2018-02529","lead_sponsor":"University of California, San Francisco","biomarkers":" PD-L1 • IFNG • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression","tags":["PD-L1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2024-06-25"},{"id":"7258fe47-fdbb-4505-b15b-20957550273b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04303117","created_at":"2021-01-18T20:52:07.511Z","updated_at":"2024-07-02T16:34:26.828Z","phase":"Phase 1/2","brief_title":"NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma","source_id_and_acronym":"NCT04303117","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-12"},{"id":"25671921-cedc-4c83-9415-f58675a747fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03993106","created_at":"2021-01-29T07:19:27.297Z","updated_at":"2024-07-02T16:35:06.312Z","phase":"Phase 2","brief_title":"A Study of sEphB4-HSA in Kaposi Sarcoma","source_id_and_acronym":"NCT03993106","lead_sponsor":"Vasgene Therapeutics, Inc","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sEphB4-HSA"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 09/17/2020","start_date":" 09/17/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-02"},{"id":"8deded4a-9926-4f1a-a26a-90e378ae94dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577755","created_at":"2023-11-14T19:14:53.297Z","updated_at":"2024-07-02T16:35:08.364Z","phase":"Phase 2","brief_title":"Pomalidomide Treatment in Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT04577755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-22"},{"id":"43f9829a-fbb2-49ae-a022-93bd3aff42fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02408861","created_at":"2021-01-18T11:30:20.490Z","updated_at":"2024-07-02T16:35:12.161Z","phase":"Phase 1","brief_title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02408861","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • CD4","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/21/2015","start_date":" 10/21/2015","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-01"},{"id":"060e7871-5a8c-4f16-a224-6a753b1ca603","acronym":"","url":"https://clinicaltrials.gov/study/NCT05859074","created_at":"2023-05-15T14:04:26.274Z","updated_at":"2024-07-02T16:35:19.241Z","phase":"Phase 1","brief_title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05859074","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MQ710"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/04/2023","start_date":" 05/04/2023","primary_txt":" Primary completion: 05/04/2028","primary_completion_date":" 05/04/2028","study_txt":" Completion: 05/04/2028","study_completion_date":" 05/04/2028","last_update_posted":"2024-02-15"},{"id":"277cef5a-ecd7-472f-ac18-a91f7891a25f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02595866","created_at":"2021-01-18T12:35:54.152Z","updated_at":"2024-07-02T16:35:30.462Z","phase":"Phase 1","brief_title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","source_id_and_acronym":"NCT02595866","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • CD4","pipe":" | ","alterations":" BRAF V600 • ALK mutation • ROS1 mutation","tags":["PD-L1 • BRAF • ALK • ROS1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/04/2016","start_date":" 04/04/2016","primary_txt":" Primary completion: 10/04/2023","primary_completion_date":" 10/04/2023","study_txt":" Completion: 10/11/2024","study_completion_date":" 10/11/2024","last_update_posted":"2023-11-03"},{"id":"61383bd5-c70d-4a39-8f96-4abc92c5c78b","acronym":"STARKAP","url":"https://clinicaltrials.gov/study/NCT05646082","created_at":"2022-12-12T15:58:31.412Z","updated_at":"2024-07-02T16:35:40.433Z","phase":"Phase 1","brief_title":"Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma","source_id_and_acronym":"NCT05646082 - STARKAP","lead_sponsor":"Imperial College London","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-08-10"},{"id":"1cb3a87f-6700-43c5-97eb-2ad01d3c6932","acronym":"","url":"https://clinicaltrials.gov/study/NCT02799485","created_at":"2021-01-18T13:44:04.096Z","updated_at":"2024-07-02T16:35:44.581Z","phase":"Phase 2","brief_title":"sEphB4-HSA in Treating Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT02799485","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" EPHB4","pipe":"","alterations":" ","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sEphB4-HSA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/13/2018","start_date":" 02/13/2018","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-06-27"},{"id":"8cb93b1c-49b2-4f44-99a6-f9b982490342","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510973","created_at":"2022-08-22T13:04:28.976Z","updated_at":"2024-07-02T16:35:55.430Z","phase":"","brief_title":"Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi","source_id_and_acronym":"NCT05510973","lead_sponsor":"Elizabeth Glaser Pediatric AIDS Foundation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-02-15"},{"id":"609b62e0-5459-4e6f-b8b3-1e6b3e397774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01495598","created_at":"2022-11-05T15:11:43.110Z","updated_at":"2024-07-02T16:36:01.485Z","phase":"Phase 1/2","brief_title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","source_id_and_acronym":"NCT01495598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 01/10/2012","start_date":" 01/10/2012","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-11-01"},{"id":"d20a1a1c-6571-4f80-9551-ee94421c97f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01057121","created_at":"2021-01-29T07:00:24.457Z","updated_at":"2024-07-02T16:36:17.455Z","phase":"Phase 1/2","brief_title":"Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma","source_id_and_acronym":"NCT01057121","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/27/2010","start_date":" 08/27/2010","primary_txt":" Primary completion: 08/04/2014","primary_completion_date":" 08/04/2014","study_txt":" Completion: 08/04/2014","study_completion_date":" 08/04/2014","last_update_posted":"2022-02-08"},{"id":"b367b5cf-acb4-431a-af08-50a3f758eecd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000763","created_at":"2021-01-29T06:52:33.055Z","updated_at":"2024-07-02T16:36:21.546Z","phase":"Phase 1","brief_title":"A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma","source_id_and_acronym":"NCT00000763","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 02/01/1997","study_completion_date":" 02/01/1997","last_update_posted":"2021-11-03"},{"id":"ea14f1dd-83ae-4642-802b-7e2c102f2e24","acronym":"","url":"https://clinicaltrials.gov/study/NCT00001114","created_at":"2021-01-17T22:44:07.416Z","updated_at":"2025-02-25T14:22:45.692Z","phase":"Phase 2","brief_title":"The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma","source_id_and_acronym":"NCT00001114","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4 • IFNA1","pipe":"","alterations":" ","tags":["CD4 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 03/01/2000","study_completion_date":" 03/01/2000","last_update_posted":"2021-11-01"},{"id":"0c4ed01f-14ce-4638-8fa4-fe09d03ac925","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000954","created_at":"2021-01-29T06:52:47.531Z","updated_at":"2025-02-25T14:22:42.205Z","phase":"Phase 1/2","brief_title":"A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma","source_id_and_acronym":"NCT00000954","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • vincristine • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 09/01/1996","study_completion_date":" 09/01/1996","last_update_posted":"2021-10-29"},{"id":"894b8005-e82f-42c3-ab18-5607ff48fedb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000769","created_at":"2021-01-29T06:52:33.747Z","updated_at":"2024-07-02T16:36:22.346Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma","source_id_and_acronym":"NCT00000769","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 04/01/1998","study_completion_date":" 04/01/1998","last_update_posted":"2021-10-28"},{"id":"5fad71d4-a395-4a9d-9bc6-39b3d673e45a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01276236","created_at":"2021-01-29T07:01:30.935Z","updated_at":"2024-07-02T16:36:33.752Z","phase":"Phase 2","brief_title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","source_id_and_acronym":"NCT01276236","lead_sponsor":"University of California, San Francisco","biomarkers":" CD8 • CD38 • CD4 • CD69","pipe":" | ","alterations":" CD38 positive • CD8 negative","tags":["CD8 • CD38 • CD4 • CD69"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive • CD8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Selzentry (maraviroc)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/09/2011","start_date":" 03/09/2011","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 04/30/2015","study_completion_date":" 04/30/2015","last_update_posted":"2021-03-05"},{"id":"3fa4ebd3-233e-4045-a6de-5d818e459482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01441063","created_at":"2021-01-18T05:58:20.977Z","updated_at":"2024-07-02T16:36:39.566Z","phase":"Phase 2","brief_title":"Tocilizumab for KSHV-Associated Multicentric Castleman Disease","source_id_and_acronym":"NCT01441063","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • Valcyte (valganciclovir)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/13/2011","start_date":" 09/13/2011","primary_txt":" Primary completion: 06/06/2018","primary_completion_date":" 06/06/2018","study_txt":" Completion: 10/05/2020","study_completion_date":" 10/05/2020","last_update_posted":"2020-10-27"},{"id":"d0e34fc6-8dfa-4b6e-8743-6012fcafba7e","acronym":"REACT-KS","url":"https://clinicaltrials.gov/study/NCT01352117","created_at":"2021-01-29T07:01:54.755Z","updated_at":"2025-02-25T16:23:38.105Z","phase":"Phase 3","brief_title":"Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma","source_id_and_acronym":"NCT01352117 - REACT-KS","lead_sponsor":"AIDS Clinical Trials Group","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV"],"overall_status":"Completed","enrollment":" Enrollment 192","initiation":"Initiation: 11/18/2011","start_date":" 11/18/2011","primary_txt":" Primary completion: 03/16/2016","primary_completion_date":" 03/16/2016","study_txt":" Completion: 11/29/2018","study_completion_date":" 11/29/2018","last_update_posted":"2019-11-14"},{"id":"74b3197d-0801-4242-a057-9b8f2dd189b0","acronym":"KAPKEY","url":"https://clinicaltrials.gov/study/NCT03469804","created_at":"2021-01-17T17:45:46.624Z","updated_at":"2024-07-02T16:36:54.406Z","phase":"Phase 2","brief_title":"Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma","source_id_and_acronym":"NCT03469804 - KAPKEY","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 17","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 03/20/2020","primary_completion_date":" 03/20/2020","study_txt":" Completion: 09/20/2020","study_completion_date":" 09/20/2020","last_update_posted":"2019-10-21"},{"id":"1aec247f-d9c9-47b5-9ab1-6f77319a009e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01016730","created_at":"2021-01-18T03:59:13.786Z","updated_at":"2024-07-02T16:37:13.784Z","phase":"Phase 1","brief_title":"Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma","source_id_and_acronym":"NCT01016730","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NFKB1","pipe":"","alterations":" ","tags":["NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/22/2010","start_date":" 01/22/2010","primary_txt":" Primary completion: 01/07/2015","primary_completion_date":" 01/07/2015","study_txt":" Completion: 01/07/2015","study_completion_date":" 01/07/2015","last_update_posted":"2018-02-20"},{"id":"c5e874c6-c32f-4511-a6ed-b48b2e117537","acronym":"","url":"https://clinicaltrials.gov/study/NCT02229981","created_at":"2021-01-29T07:07:01.952Z","updated_at":"2024-07-02T16:37:15.746Z","phase":"Phase 1/2","brief_title":"Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma","source_id_and_acronym":"NCT02229981","lead_sponsor":"RedHill Biopharma Limited","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yeliva (opaganib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2017-12-07"}]